千红制药
(002550)
| 流通市值：48.61亿 | | | 总市值：68.34亿 |
| 流通股本：9.10亿 | | | 总股本：12.80亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 684,246,877.47 | 576,225,516.62 | 464,690,328.84 | 425,168,313.78 |
| 应收票据及应收账款 | 286,031,957.37 | 231,931,139.07 | 277,466,090.84 | 388,878,251.09 |
| 其中：应收票据 | 8,203,024.6 | 6,899,289.29 | 6,045,699.4 | 8,640,265.46 |
| 应收账款 | 277,828,932.77 | 225,031,849.78 | 271,420,391.44 | 380,237,985.63 |
| 应收款项融资 | 43,401,801.79 | 43,585,793.21 | 23,424,466.7 | 60,457,646.93 |
| 预付款项 | 8,449,747.17 | 3,900,900.6 | 31,431,010.55 | 19,941,144.1 |
| 其他应收款合计 | 4,631,227.88 | 16,904,047.16 | 17,861,886.24 | 4,226,283.89 |
| 存货 | 499,146,549.6 | 602,010,484.51 | 674,946,988.77 | 765,075,344.75 |
| 一年内到期的非流动资产 | - | 64,948,341.46 | - | - |
| 其他流动资产 | 1,191,655.62 | 14,487,167.55 | 573,527.76 | 328,933.58 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,579,634,177.92 | 1,625,976,769.37 | 1,528,494,252.73 | 1,712,319,838.61 |
| 非流动资产: | | | | |
| 债权投资 | 209,080,304.12 | 197,241,438.33 | 279,268,687.67 | 247,930,937.49 |
| 长期股权投资 | 5,511,360.8 | 5,978,216.97 | 2,892,232.31 | 2,806,795.41 |
| 固定资产 | 537,921,059.56 | 553,084,121.75 | 508,870,129.88 | 536,460,137.84 |
| 在建工程 | 11,236,245.57 | 8,189,094.55 | 53,316,208.38 | 59,424,776.14 |
| 无形资产 | 112,188,362.85 | 113,138,550.96 | 91,368,706.99 | 97,460,017.03 |
| 开发支出 | 76,471,843.75 | 70,162,324.03 | 55,576,955.12 | 52,272,954.37 |
| 商誉 | 11,135,053.57 | 11,135,053.57 | 11,135,053.57 | 11,135,053.57 |
| 长期待摊费用 | 22,519,407.05 | 23,602,733.69 | 19,897,685.51 | 20,785,606.88 |
| 递延所得税资产 | 93,277,733.06 | 90,526,780.93 | 96,501,662.29 | 97,710,303.38 |
| 其他非流动资产 | 69,745,620 | 67,046,360 | 90,900,325 | 85,615,410.21 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,149,086,990.33 | 1,140,104,674.78 | 1,209,727,646.72 | 1,211,601,992.32 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,728,721,168.25 | 2,766,081,444.15 | 2,738,221,899.45 | 2,923,921,830.93 |
| 流动负债: | | | | |
| 短期借款 | 56,213,623.54 | 55,622,730.9 | 20,021,666.67 | 300,551,734.46 |
| 应付票据及应付账款 | 37,686,119.12 | 41,176,407.88 | 35,507,060.63 | 51,032,658.44 |
| 应付账款 | 37,686,119.12 | 41,176,407.88 | 35,507,060.63 | 51,032,658.44 |
| 合同负债 | 2,144,402.88 | 9,705,888.09 | 3,173,548.31 | 28,107,576.75 |
| 应付职工薪酬 | 19,918,056.2 | 38,855,524.46 | 36,090,956.95 | 23,444,477.28 |
| 应交税费 | 17,618,842.81 | 6,331,619.64 | 22,028,025.03 | 14,705,589.8 |
| 其他应付款合计 | 11,468,729.83 | 7,957,026.27 | 8,008,879.82 | 7,429,138.05 |
| 其他流动负债 | 63,216,588.67 | 46,161,743.29 | 46,328,578.61 | 45,102,055.4 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 208,266,363.05 | 205,810,940.53 | 171,158,716.02 | 470,373,230.18 |
| 非流动负债: | | | | |
| 递延收益 | 82,985,038.45 | 81,845,538.84 | 83,396,383.9 | 85,369,430.65 |
| 递延所得税负债 | 4,307,448.63 | 4,516,468.27 | 4,391,497.62 | 4,580,238.74 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 87,292,487.08 | 86,362,007.11 | 87,787,881.52 | 89,949,669.39 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 295,558,850.13 | 292,172,947.64 | 258,946,597.54 | 560,322,899.57 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,279,800,000 | 1,279,800,000 | 1,279,800,000 | 1,279,800,000 |
| 资本公积 | 41,653,809.86 | 41,653,809.86 | 40,067,587.24 | 36,288,651.51 |
| 减:库存股 | 170,863,806.25 | 30,093,633.31 | 30,093,633.31 | 30,093,633.31 |
| 其他综合收益 | -967,007.72 | 355,701.26 | -1,630,468.21 | -474,497.46 |
| 盈余公积 | 289,236,431.28 | 289,236,431.28 | 274,113,896.47 | 274,113,896.47 |
| 未分配利润 | 978,086,856.27 | 873,978,695.92 | 905,095,590.37 | 826,266,320.35 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,416,946,283.44 | 2,454,931,005.01 | 2,467,352,972.56 | 2,385,900,737.56 |
| 少数股东权益 | 16,216,034.68 | 18,977,491.5 | 11,922,329.35 | -22,301,806.2 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,433,162,318.12 | 2,473,908,496.51 | 2,479,275,301.91 | 2,363,598,931.36 |
| 负债和股东权益合计 | 2,728,721,168.25 | 2,766,081,444.15 | 2,738,221,899.45 | 2,923,921,830.93 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-25 | 2023-07-22 |
| 审计意见(境内) | | 标准无保留意见 | | |